search
Back to results

Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers

Primary Purpose

Hypertension

Status
Unknown status
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
D935 Cap. 1T
CKD-385 Tab. 1T
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Chronic stable angina, Congestive Heart Failure

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. A healthy adult aged over 19 at the time of screening
  2. Weight over 55, with BMI between 17.5kg/m² and 30.5kg/m²
  3. Subject who has no congenital or chronic disease within the last 3 years and no medical symptoms or signs as a result of medical examination
  4. Suitable subject who is determined at the time of screening by examiners according to the characteristics of the medicine such as hematology test, blood chemistry test, urine test, virus / bacteriological test, vital signs, electrocardiogram test
  5. Subject who signed the written consent form approved by Chonbuk National University Hospital IRB to participate in this study with full understanding of the purpose and contents of the examination prior to participation of the clinical trial
  6. Subject who has the ability and willingness to participate in the clinical trial

Exclusion Criteria:

  1. Subject who has (or has histories of) clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic diseases(except for asymptomatic seasonal allergy at the time of administration) or evidence(except for simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.)
  2. Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect the absorption of drug
  3. Subject who shows the following values as a result of laboratory tests

    *ALT or AST > 2 times upper limit of normal range

  4. Subject who has a history of regular alcohol consumption in excess of 210 g/week within 6 months of screening
  5. Subject who smokes more than one pack of cigarette a day within 6 months of screening
  6. Subject who took other clinical trial drugs or bioequivalence test drugs within 3 months before the first administration of clinical trial drug
  7. Subject who conform to the specific items below

    • systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position
    • Severe bradycardia (less than 50 beats/minute)
  8. Subject who has significant alcohol abuse or drug abuse within a year of screening
  9. Subject who took drugs which are known as disturbing drug metabolism within 30 days prior to the first administration of clinical trial drug.
  10. Subject who uses any of other drugs, including over-the-counter medications and prescription medications within 10 days prior to first administration of clinical trial drug.
  11. Subject who donated whole blood within 2 months prior to first administration of clinical trial drug or blood components within 1 month prior to first administration of clinical trial drug
  12. Subject who is hypersensitive to the components of a clinical trial drug or clinical trial drug itself.
  13. Subject who does not consent to reliable contraception during the entire period of clinical trial and until 7th day of administration of clinical trial drug.
  14. Subject who is not able to consume high-fat meal provided during the clinical trial
  15. Any other subject who is decided by investigators to be ineligible in clinical trial

Sites / Locations

  • Chonbuk National University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Group 1

Group 2

Arm Description

D935 Cap. 1T

CKD-385 Tab. 1T

Outcomes

Primary Outcome Measures

AUCt of Carvedilol
Area under the plasma concentration of Carvedilol verses time curve from time zero to time of last quantifiable concentration
Cmax of Carvedilol
Maximum plasma concentration of Carvedilol

Secondary Outcome Measures

AUCinf of Carvedilol
Area under the plasma concentration of Carvedilol versus time curve from time zero to time infinity
Tmax of Carvedilol
Time to maximum concentration of Carvedilol
t1/2 of Carvedilol
Terminal elimination half-life of Carvedilol
CL/F of Carvedilol
Total body clearance of Carvedilol
Vd/F of Carvedilol
Apparent volume of distribution of Carvedilol

Full Information

First Posted
November 18, 2018
Last Updated
December 27, 2018
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT03748212
Brief Title
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers
Official Title
A Randomized, Open-label, Fed, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Unknown status
Study Start Date
October 24, 2018 (Actual)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
Detailed Description
To healthy subjects of 52, following treatments are administered dosing in each period and wash-out period is a minimum of 7 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Chronic stable angina, Congestive Heart Failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
52 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Active Comparator
Arm Description
D935 Cap. 1T
Arm Title
Group 2
Arm Type
Experimental
Arm Description
CKD-385 Tab. 1T
Intervention Type
Drug
Intervention Name(s)
D935 Cap. 1T
Other Intervention Name(s)
D935
Intervention Description
single oral administration under fed condition
Intervention Type
Drug
Intervention Name(s)
CKD-385 Tab. 1T
Other Intervention Name(s)
CKD-385
Intervention Description
single oral administration under fed condition
Primary Outcome Measure Information:
Title
AUCt of Carvedilol
Description
Area under the plasma concentration of Carvedilol verses time curve from time zero to time of last quantifiable concentration
Time Frame
Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Title
Cmax of Carvedilol
Description
Maximum plasma concentration of Carvedilol
Time Frame
Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Secondary Outcome Measure Information:
Title
AUCinf of Carvedilol
Description
Area under the plasma concentration of Carvedilol versus time curve from time zero to time infinity
Time Frame
Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Title
Tmax of Carvedilol
Description
Time to maximum concentration of Carvedilol
Time Frame
Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Title
t1/2 of Carvedilol
Description
Terminal elimination half-life of Carvedilol
Time Frame
Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Title
CL/F of Carvedilol
Description
Total body clearance of Carvedilol
Time Frame
Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Title
Vd/F of Carvedilol
Description
Apparent volume of distribution of Carvedilol
Time Frame
Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: A healthy adult aged over 19 at the time of screening Weight over 55, with BMI between 17.5kg/m² and 30.5kg/m² Subject who has no congenital or chronic disease within the last 3 years and no medical symptoms or signs as a result of medical examination Suitable subject who is determined at the time of screening by examiners according to the characteristics of the medicine such as hematology test, blood chemistry test, urine test, virus / bacteriological test, vital signs, electrocardiogram test Subject who signed the written consent form approved by Chonbuk National University Hospital IRB to participate in this study with full understanding of the purpose and contents of the examination prior to participation of the clinical trial Subject who has the ability and willingness to participate in the clinical trial Exclusion Criteria: Subject who has (or has histories of) clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic diseases(except for asymptomatic seasonal allergy at the time of administration) or evidence(except for simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.) Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect the absorption of drug Subject who shows the following values as a result of laboratory tests *ALT or AST > 2 times upper limit of normal range Subject who has a history of regular alcohol consumption in excess of 210 g/week within 6 months of screening Subject who smokes more than one pack of cigarette a day within 6 months of screening Subject who took other clinical trial drugs or bioequivalence test drugs within 3 months before the first administration of clinical trial drug Subject who conform to the specific items below systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position Severe bradycardia (less than 50 beats/minute) Subject who has significant alcohol abuse or drug abuse within a year of screening Subject who took drugs which are known as disturbing drug metabolism within 30 days prior to the first administration of clinical trial drug. Subject who uses any of other drugs, including over-the-counter medications and prescription medications within 10 days prior to first administration of clinical trial drug. Subject who donated whole blood within 2 months prior to first administration of clinical trial drug or blood components within 1 month prior to first administration of clinical trial drug Subject who is hypersensitive to the components of a clinical trial drug or clinical trial drug itself. Subject who does not consent to reliable contraception during the entire period of clinical trial and until 7th day of administration of clinical trial drug. Subject who is not able to consume high-fat meal provided during the clinical trial Any other subject who is decided by investigators to be ineligible in clinical trial
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kyung-Ho Jang
Phone
+82-63-259-3500
Email
khjang@jbcp.kr
First Name & Middle Initial & Last Name or Official Title & Degree
Min-Gul Kim
Email
mgkim@jbcp.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyung-Ho Jang
Organizational Affiliation
Chonbuk National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chonbuk National University Hospital
City
Jeonju
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kyung-Ho Jang, Professor

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers

We'll reach out to this number within 24 hrs